Payment for antiretroviral drugs is associated with a higher rate of patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue 3, 2008, Pages 288-293

  Zachariah, R ^a   Van Engelgem, I ^a   Massaquoi, M ^a   Kocholla, L ^b   Manzi, M ^a   Suleh, A ^b   Phillips, M ^c   Borgdorff, M ^d  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MINISTRY OF HEALTH   (Kenya)

^c MÉDECINS SANS FRONTIÈRES   (Belgium)

^d Ministry of Health ^*

Author keywords

AIDS; Antiretroviral therapy; HIV; Kenya; Loss to follow up; Payment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; COVIRO LS; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; TIOMUNE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KENYA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NONHUMAN; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK REDUCTION; TABLET;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CONTINUITY OF PATIENT CARE; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; KENYA; MALE; PATIENT COMPLIANCE; PRESCRIPTION FEES; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; STATISTICS AS TOPIC; TREATMENT REFUSAL;

EID: 39149142511     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2007.12.007     Document Type: Article

References (25)

1. Bell C., Deverajan S., and Gersbach H. Thinking About the Long-run Economic Cost of AIDS. In: Haacker M. (Ed). The Macroeconomics of HIV/AIDS (2004), IMF, Washington, DC
2. Bission G.P., Frank I., Gross R., Vincent L., Jordan B., Wang X., Mogorosi M., Gaolathe T., Ndwapi N., Friedman H., Strom B., and Dickinson D. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 9 (2006) 1333-1336
3. Braitstein P., Brinkhof M.W., Dabis F., Schechter M., Boulle A., Miotti P., Wood R., Laurent C., Sprinz E., Seyler C., Bangsberg D.R., Balestre E., Sterne J.A., May M., Egger M., and Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824
4. Byakika-Tusiimi J., Oyigi J.H., Tumwikirize W.A., Katabira E.T., Mugyenyi P.N., and Bangsberg D.R. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int. J. STD AIDS 16 (2005) 38-41
5. Harries A.D., Nyangulu D.S., Hargreaves N.J., Kaluwa O., and Salaniponi F.M. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358 (2001) 410-414
6. Ivers L.C., Kendrick D., and Doucette K. Efficacy of antiretroviral therapy programmes in resource-poor settings: a meta-analysis of the published literature. Clin. Infect. Dis. 41 (2005) 217-224
7. Karcher H., Omondi A., Odera J., Kunz A., and Harms G. Risk factors for treatment denial and loss to follow up in an antiretroviral treatment cohort in Kenya. Trop. Med. Int. Health 12 (2007) 687-694
8. Laniece I., Mounirou C., and Desclaux A. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 17 Suppl. 3 (2003) S103-S108
9. Laurent C., Meilo H., Guiard S., Mapoure Y., Noel J.M., M'Bangue M., Joko A., Rozenbaum W., Ntone F., and Delaporte E. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin. Infect. Dis. 41 (2005) 108-111
10. MOH. Ministry of Health. Strategic Plan for the National ART Programme in Kenya 2004-2008 (2004), Ministry of Health, Nairobi, Kenya
11. MOH. Kenyan National Clinical Manual for ARV Providers. first ed. (2004), Ministry of Health, Nairobi, Kenya
12. Oosterhout V.J., Bodasing N., Kumwenda J., Nyrinda C., Maliewa J., Cleary P., Baar D.M., Schuurman R., Burger D.M., and Zijlstra E. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop. Med. Int. Health 10 (2005) 464-470
13. Remien R.H., Bastos F.I., Berkman A., Terto V., Raxach J.C., and Parker R.G. Universal access to antiretroviral therapy may be the best approach to "Do No Harm" in developing countries: the Brazilian experience. AIDS 17 (2003) 786-787
14. Russel S. The economic burden of illness for households in developing countries: a review of studies focusing on Malaria, Tuberculosis and Human Immunodeficiency Syndrome. Am J. Trop. Med. Hyg. 71 (2004) 147-155
15. Sepehri A., and Chernomas A. Are user charges efficiency and equity enhancing? A critical review of economic literature with particular reference to experience from developing countries. J. Int. Dev. 13 (2001) 183-209
16. UNAIDS, 2007. Uniting the World Against AIDS - Kenya. http://www.unaids.org/en/Regions_Countries/Countries/kenya.asp [accessed November 2007].
17. UNDP, 2006. Kenya National Human Development Report 2006. http://hdr.undp.org/en/reports/nationalreports/africa/kenya/name,3451,en.html [accessed November 2007].
18. Ventelou B., and Drouhin N. AIDS and economic growth in Africa. In: Moatti J.P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., and Flori Y.A. (Eds). Economics of AIDS and Access to HIV/AIDS Care in Developing Countries. Issues and Challenges (2003), Agence Nationale de Recherches sur la Sida, Paris, France
19. Weiser S., Wolfe W., and Bangsberg D. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J. Acquir. Immune Defic. Syndr. 34 (2003) 281-288
20. WHO, 2003. Giving tuberculosis a human face. Global advocacy report 2003 World Health Organization, Geneva, WHO/CDS/TB/2003.321. http://www.who.int/tb/publications/advocacy_report_2003/en/ [accessed November 2007].
21. WHO, 2005a. Progress on Global Access to HIV Antiretroviral Therapy. An update on '3 by 5'. Available online at: http://www.who.int/3by5/fullreportJune2005.pdf [accessed January 2008].
22. WHO, 2005b. The Practice of Charging User Fees at the Point of Service Delivery for HIV/AIDS Treatment and Care. World Health Organization, Geneva, WHO/HIV/2005.11.
23. Wools-Kaloustian K., Kimaiyo S., Diero L., Siika A., Sidle J., Yiannoutsos C.T., Musick B., Einterz R., Fife K.H., and Tierney W.M. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20 (2006) 41-48
24. World Bank, 2006. Key Development Data and Statistics. http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS.html [accessed November 2007].
25. Yu J.K., Chen S.C., Wang K.Y., Chang C.S., Makombe S.D., Schouten E.J., and Harries A.D. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull. World Health Organ. 85 (2007) 550-554